Nucleome Therapeutics announces Dr. Michelle Morrow as CSO effective February 23, 2026, bringing two decades of drug discovery experience as the company advances lead candidate NTP464 toward IND enabling studies.
Roche announced positive Phase III MAJESTY trial results showing Gazyva achieved significantly higher complete remission rates at two years versus tacrolimus in primary membranous nephropathy, with no new safety signals identified.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07590635 |
eCardiacRehab - a Hybrid Patient-Centered eHealth Programme |
NOT_YET_RECRUITING | NA |
| NCT07556250 |
Investigating Cognitive Flexibility Training |
NOT_YET_RECRUITING | NA |
| NCT07516496 |
Metabolic Phenotyping in vEDS |
RECRUITING | |
| NCT07498829 |
Population Based Germline Testing for Early Detection and Prevention of Cancer |
RECRUITING | NA |
| NCT07496775 |
Cardiovascular Acoustics for Early Disease Detection |
NOT_YET_RECRUITING | |
| NCT07341230 |
Deep Brain Stimulation to Understand and Treat Addiction |
RECRUITING | NA |
| NCT07289100 |
Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis |
RECRUITING | |
| NCT07283913 |
Non-invasive Ultrasonic Auricular Vagus Nerve Stimulation |
RECRUITING | NA |
| NCT07267325 |
Bone Health in Postmenopausal Women: The Effect of Exercise With or Without Medication for Osteoporosis |
NOT_YET_RECRUITING | NA |
| NCT07238049 |
REAl World Dementia OUTcomes: Observational Study |
ENROLLING_BY_INVITATION |
